arrow_back

search

search

sort

next_plan

Our mRNA fears

expand_more

136K views1 year ago

thumb_upLike

thumb_downDislike

library_addSave

flagReport

Dr. John Campbell check_circle

2K subscribers

Short and long term adverse events following covid vaccination. With thanks to Professor Robert Clancy

physiology,nursing,NCLEX,health,disease,biology,medicine,nurse education,medical education,pathophysiology,campbell,human biology,human body,zGcX5q7319E,, Health,Knowledge, channel_UCF9IOB2TExg3QIBupFtBDxg, video_zGcX5q7319E

vid:260182

Comments0

unfold_more

Useless eaters like me

Dr. John Campbell check_circle

101K views 1 year ago

Insulin resistance with Dr. Dhand

Dr. John Campbell check_circle

95K views 1 year ago

Vaccine injuries, full version

Dr. John Campbell check_circle

82K views 1 year ago

Great interview with Jimmy Dore

Dr. John Campbell check_circle

47K views 1 year ago

mRNA in our cells (part 2)

Dr. John Campbell check_circle

56K views 1 year ago

keyboard_arrow_left

Alex Jones Show

Bannons War Room

navigate_next

Ivermectin research

Dr. John Campbell check_circle

167K views 1 year ago

,With Professor Colleen Aldous Critical appraisal of multidrug therapy in the ambulatory management of patients with COVID-19 and hypoxemia Part II: Causal inference using the Bradford Hill criteria https://www.jstage.jst.go.jp/article/antibiotics/78/1/78_35/_pdf/-char/en We continue the critical appraisal of three published case series of 119 COVID-19 patients with hypoxemia, treated in the United States, Zimbabwe, and Nigeria with similar ivermectin-based multidrug treatments, to assess the available evidence supporting a causal relationship between treatment and reduction in hospitalizations and mortality. A narrative review was conducted to assess the Bradford Hill criteria for a causal association. We used a previously proposed refinement of the Bradford Hill criteria that reorganized them into three categories of direct, mechanistic, and parallel evidence. The efficacy of the two most aggressive ivermectin-based multidrug protocols is supported by the Bradford Hill criteria for temporality, strength of association, biological gradient, biological plausibility, coherence, consistency, and analogy. The causal relation between the treatment of hypoxemic COVID-19 patients using these protocols and the reduction in hospitalizations and mortality is supported as an inference to the best explanation. Critical appraisal of multidrug therapy in the ambulatory management of patients with COVID-19 and hypoxemia Part I. Evidence supporting the strength of association https://faculty.utrgv.edu/eleftherios.gkioulekas/papers/032-c19-ivm-oxygen.pdf On March 11, 2020, Coronavirus Disease 2019 (COVID-19), the disease caused by the Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization (WHO) [1]. Worldwide, 768,187,096 confirmed cases of COVID-19 and 6,945,714 deaths have been reported to the WHO as of June 21 2023, amounting to an average Case Fatality Rate (CFR) of 0.9% [2]. During 2020, while several governments and public health agencies were focused on contagion control and in-hospital patient care, several medical doctors from all around the world innovated and discovered early outpatient multidrug treatments using several repurposed medications in combination [3–15]. In the United States, several independent efforts coalesced into the formulation of a sequenced multidrug protocol [10, Fig. 3] (hereafter, McCullough protocol), which is based on the pathophysiological understanding of COVID-19 as a triphasic illness with three overlapping phases: (1) viral proliferation; (2) hyperinflammatory cytokine storm (COVID-19 pneumonia); and (3) thrombosis. McCullough’s protocol proposed a combination antiviral therapy for treating the viral proliferation phase, immunomodulators for treating the cytokine storm, and antiplatelet agents and antithrombotics for handling the thrombotic stage, based on risk stratification and how the disease presents in each individual patient. Thus, the McCullough protocol is an algorithmic treatment using sequenced multiple drugs in combination and customized to the individual patient and their response to treatment; no single drug is necessary nor sufficient to achieve treatment efficacy towards reducing hospitalizations and deaths. A recently published update of the McCullough protocol [16, Fig. 3] introduced some adjustments including virucidal nasal washes and oral gargles [17–24]. A large case series of 869 high-risk patients [25, 26], who were treated using an early version of the McCullough protocol, has been compared against population-level and historical controls [27], showing the existence of efficacy with respect to the reduction of mortality and hospitalizations, which is also resilient with respect to random selection bias, provided that patients are treated early enough within the first 3 to 5 days from the onset of illness. Indeed, an earlier study by Fazio et al.[28] showed that the ideal window of opportunity for initiating an effective early outpatient treatment of COVID-19 to prevent hospitalization is approximately within the first 3 days.

Cancer free after mushroom

Dr. John Campbell check_circle

215K views 1 year ago

Increased cancers after mRNA vaccines

Dr. John Campbell check_circle

177K views 1 year ago

,COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province https://pubmed.ncbi.nlm.nih.gov/40881928/ https://pmc.ncbi.nlm.nih.gov/articles/PMC12381369/ https://www.thefocalpoints.com/p/breaking-first-population-wide-study The rate of first hospitalization for cancer of any site Unvaccinated group: 0.85% Vaccinated group (one or more doses): 1.15% N = 296,015 population Hospital admission with a cancer diagnosis, 3,124 (p less than 0.001). Vaccination with at least one dose Colon-rectal cancer HR: 1.34 Breast cancer HR: 1.54 Bladder cancer HR: 1.62 After three or more vaccine doses Breast cancer HR: 1.36 Bladder cancer HR: 1.43 All significant After one dose (180 days after) Rate of first hospital admissions for cancers All cancers: up 23% significant Colorectal: up 34% significant Lung: down = 10% Breast: up 54% significant Uterine: up = 75% Ovarian: up = 65% Prostate: up = 1% Bladder: up 62% significant Thyroid: up =58% Haematological: up = 33% After three dose (180 days after administration of third dose) All cancers: up = 9% Colorectal: up = 14% Lung: down = 5% Breast: up=36% significant Uterine: up = 20% Ovarian: up = 86% Prostate: down = 3% Bladder: up=43% significant Thyroid: down = 3% Haematological: up = 5% More about the study Population-wide cohort analysis Evaluating the risk of all-cause death and cancer hospitalization by SARS-CoV-2 immunization status. National Health System official data, entire population, Pescara province, Italy Followed from June 2021 (six months after the first vaccination) to December 2023. 296,015 residents aged ≥11 years Hospital admission with a cancer diagnosis, 3,124 16.6% were unvaccinated 83.3% received ≥1 dose 62.2% ≥3 doses. Compared with the unvaccinated, those receiving ≥1 dose showed a significantly lower likelihood of all-cause death Cancer hospitalization was significant only among the subjects with no previous SARS-CoV-2 infection Some cancer risks went down after 1 year (relative to 180 days) (But breast, ovarian and bladder went up at one year relative to 180 days after 1 vaccine dose) Given that it was not possible to quantify the potential impact of the healthy vaccinee bias and unmeasured confounders, these findings are inevitably preliminary.

Spike and disease

Dr. John Campbell check_circle

293K views 1 year ago

White clots in 2025

Dr. John Campbell check_circle

178K views 1 year ago

Dr. John Campbell check_circle

136K views 1 year ago

Madness of Crowds

Dr. John Campbell check_circle

214K views 1 year ago